228 related articles for article (PubMed ID: 35674661)
1. Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study.
Nowakowski GS; Yoon DH; Peters A; Mondello P; Joffe E; Fleury I; Greil R; Ku M; Marks R; Kim K; Zinzani PL; Trotman J; Huang D; Waltl EE; Winderlich M; Kurukulasuriya NC; Ambarkhane S; Hess G; Salles G
Clin Cancer Res; 2022 Sep; 28(18):4003-4017. PubMed ID: 35674661
[TBL] [Abstract][Full Text] [Related]
2. RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
Nowakowski GS; Yoon DH; Mondello P; Joffe E; Peters A; Fleury I; Greil R; Ku M; Marks R; Kim K; Zinzani PL; Trotman J; Sabatelli L; Waltl EE; Winderlich M; Sporchia A; Kurukulasuriya NC; Cordoba R; Hess G; Salles G
Ann Hematol; 2023 Jul; 102(7):1773-1787. PubMed ID: 37171597
[TBL] [Abstract][Full Text] [Related]
3. Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
Cordoba R; Prawitz T; Westley T; Sharma A; Ambarkhane S; Kapetanakis V; Sabatelli L
Adv Ther; 2022 Jun; 39(6):2668-2687. PubMed ID: 35403948
[TBL] [Abstract][Full Text] [Related]
4. RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Zinzani PL; Rodgers T; Marino D; Frezzato M; Barbui AM; Castellino C; Meli E; Fowler NH; Salles G; Feinberg B; Kurukulasuriya NC; Tillmanns S; Parche S; Dey D; Fingerle-Rowson G; Ambarkhane S; Winderlich M; Nowakowski GS
Clin Cancer Res; 2021 Nov; 27(22):6124-6134. PubMed ID: 34433649
[TBL] [Abstract][Full Text] [Related]
5. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Salles G; Duell J; González Barca E; Tournilhac O; Jurczak W; Liberati AM; Nagy Z; Obr A; Gaidano G; André M; Kalakonda N; Dreyling M; Weirather J; Dirnberger-Hertweck M; Ambarkhane S; Fingerle-Rowson G; Maddocks K
Lancet Oncol; 2020 Jul; 21(7):978-988. PubMed ID: 32511983
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Duell J; Maddocks KJ; González-Barca E; Jurczak W; Liberati AM; De Vos S; Nagy Z; Obr A; Gaidano G; Abrisqueta P; Kalakonda N; André M; Dreyling M; Menne T; Tournilhac O; Augustin M; Rosenwald A; Dirnberger-Hertweck M; Weirather J; Ambarkhane S; Salles G
Haematologica; 2021 Sep; 106(9):2417-2426. PubMed ID: 34196165
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of polatuzumab-bendamustine-rituximab
Calamia M; McBride A; Abraham I
J Med Econ; 2021 Nov; 24(sup1):14-24. PubMed ID: 34866523
[TBL] [Abstract][Full Text] [Related]
8. Broadening the MIND: Tafasitamab and Lenalidomide versus Synthetic Controls.
Cherng HJ; Westin JR
Clin Cancer Res; 2022 Sep; 28(18):3908-3910. PubMed ID: 35861632
[TBL] [Abstract][Full Text] [Related]
9. Clinical Treatment Guidelines for Tafasitamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Nedved A; Maddocks K; Nowakowski GS
Oncologist; 2023 Mar; 28(3):199-207. PubMed ID: 36648324
[TBL] [Abstract][Full Text] [Related]
10. A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Czuczman MS; Trněný M; Davies A; Rule S; Linton KM; Wagner-Johnston N; Gascoyne RD; Slack GW; Brousset P; Eberhard DA; Hernandez-Ilizaliturri FJ; Salles G; Witzig TE; Zinzani PL; Wright GW; Staudt LM; Yang Y; Williams PM; Lih CJ; Russo J; Thakurta A; Hagner P; Fustier P; Song D; Lewis ID
Clin Cancer Res; 2017 Aug; 23(15):4127-4137. PubMed ID: 28381416
[No Abstract] [Full Text] [Related]
11. Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.
Belada D; Kopeckova K; Bergua Burgues JM; Stevens D; André M; Persona EP; Pichler P; Staber PB; Trneny M; Duell J; Waldron-Lynch M; Wagner S; Mukhopadhyay A; Dirnberger-Hertweck M; Burke JM; Nowakowski GS
Blood; 2023 Oct; 142(16):1348-1358. PubMed ID: 37369099
[TBL] [Abstract][Full Text] [Related]
12. Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
Salles G; Długosz-Danecka M; Ghesquières H; Jurczak W
Expert Opin Biol Ther; 2021 Apr; 21(4):455-463. PubMed ID: 33554668
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma treatment options-Experience of the efficiency frontier approach.
Kurte MS; Siefen AC; Jakobs F; von Tresckow B; Reinhardt HC; Kron F
Eur J Haematol; 2023 Dec; 111(6):895-908. PubMed ID: 37644352
[TBL] [Abstract][Full Text] [Related]
14. Tafasitamab: First Approval.
Hoy SM
Drugs; 2020 Nov; 80(16):1731-1737. PubMed ID: 32946059
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL.
Goy A; Ramchandren R; Ghosh N; Munoz J; Morgan DS; Dang NH; Knapp M; Delioukina M; Kingsley E; Ping J; Beaupre DM; Neuenburg JK; Ruan J
Blood; 2019 Sep; 134(13):1024-1036. PubMed ID: 31331917
[TBL] [Abstract][Full Text] [Related]
16. Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma.
Lu Q; Huang H; Tang S; Wang Y; Yang DH
Drugs Today (Barc); 2021 Sep; 57(9):571-580. PubMed ID: 34586105
[TBL] [Abstract][Full Text] [Related]
17. Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study.
Duell J; Abrisqueta P; Andre M; Gaidano G; Gonzales-Barca E; Jurczak W; Kalakonda N; Liberati AM; Maddocks KJ; Menne T; Nagy Z; Tournilhac O; Kuffer C; Bakuli A; Amin A; Gurbanov K; Salles G
Haematologica; 2024 Feb; 109(2):553-566. PubMed ID: 37646664
[TBL] [Abstract][Full Text] [Related]
18. Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation.
Cazelles C; Belhadj K; Vellemans H; Camus V; Poullot E; Gaulard P; Veresezan L; Itti E; Becker S; Carvalho M; Dupuis J; Le Bras F; Lemonnier F; Roulin L; El Gnaoui T; Jardin F; Mounier N; Tilly H; Haioun C
Leuk Lymphoma; 2021 Sep; 62(9):2161-2168. PubMed ID: 33764240
[TBL] [Abstract][Full Text] [Related]
19. Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis.
Hong JY; Yoon DH; Suh C; Kim WS; Kim SJ; Jo JC; Kim JS; Lee WS; Oh SY; Park Y; Kim SY; Lee MH; Lee HS; Do YR
Ann Hematol; 2018 Aug; 97(8):1437-1443. PubMed ID: 29619501
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial.
Shen QD; Zhu HY; Wang L; Fan L; Liang JH; Cao L; Wu W; Xia Y; Li JY; Xu W
Lancet Haematol; 2018 Jun; 5(6):e261-e269. PubMed ID: 29752199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
